Virtual Library
Start Your Search
Q. Li
Author of
-
+
P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.01-076 - Efficacy and Safety of Recombinant Human Tumor Necrosis Factor Application for the Treatment of Malignant Pleural Effusion Caused by Lung Cancer (ID 1148)
09:30 - 09:30 | Author(s): Q. Li
- Abstract
Background:
Malignant pleural effusion (MPE) is mainly caused by metastatic pleural cancer and defines malignant tumors with a poor prognosis. To achieve sufficient control of MPE and to minimize invasive interventions are the primary goals of the treating physicians. Recombinant human mutant tumor necrosis factor-alpha (rhu-TNF) has been used in the treatment of MPE. The aim of our research study, which included a total of 102 patients with MPE caused by lung cancer, was retrospectively to evaluate efficacy and safety of rhu-TNF application via ultrasound-guided chest tube for the treatment of MPE. Malignant pleural effusion (MPE) is mainly caused by metastatic pleural cancer and defines malignant tumors with a poor prognosis. To achieve sufficient control of MPE and to minimize invasive interventions are the primary goals of the treating physicians. Recombinant human mutant tumor necrosis factor-alpha (rhu-TNF) has been used in the treatment of MPE. The aim of our research study, which included a total of 102 patients with MPE caused by lung cancer, was retrospectively to evaluate efficacy and safety of rhu-TNF application via ultrasound-guided chest tube for the treatment of MPE.
Methods:
Rhu-TNF was administered as a single dose to 102 patients, and dexamethasone (Dmx, 5 mg) was administered 30 min before rhu-TNF in 35 patients in order to prevent side effects. The primary endpoint was the efficacy of the Rhu-TNF treatment (disease response rate) and side effects (pain, fever and flu-like symptoms) evaluated four weeks after instillation.
Results:
The disease response rate of Rhu-TNF treatment in 102 patients was 81.37%. Side effects included 13 (12.75%) patients complaining about flu-like symptoms, 15 (14.71%) with fever/chill, and 14 (13.73%) with chest pain. A significantly higher efficacy was observed for the treatment with three versus two million units rhu-TNF (= 0.036), while the adverse effects were similar. Although application of Dmx before the intra-pleural instillation of rhu-TNF reduced the incidence of adverse events, no significant differences were found.
Conclusion:
In conclusion, our study shows that intra-pleural instillation of rhu-TNF in MPE patients achieves sufficient control of MPE and minimizes invasive interventions.
